Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06453486
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-11
First Post:
2024-06-05
Brief Title:
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Ablative Radiation Therapy With High Dose Geometric Boost for Locally Advanced Pancreatic Cancer Following Treatment Response Evaluation of Induction Chemotherapy a Phase II Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ABLATE
Brief Summary:
The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer The main question it aims to answer is
For patients with locally advanced pancreatic cancer that responded to initial chemotherapy stayed stable or decreased in size will high-dose RT radiation therapy contribute to improving treatment outcomes enhancing quality of life or increasing overall survival rates
Participants will
Undergo a tumor biopsy
Undergo induction chemotherapy chemotherapy given before radiation therapy with modified FOLFIRINOX FFX or gemcitabine and nab-paclitaxel GnP
If the participants disease remains stable or improves after chemotherapy they will be treated with high dose radiation therapy If the participants cancer progresses after chemotherapy they will be treated by their doctor according to standard of care practices
Complete quality of life questionnaires
Donate research blood samples
For patients with locally advanced pancreatic cancer that responded to initial chemotherapy stayed stable or decreased in size will high-dose RT radiation therapy contribute to improving treatment outcomes enhancing quality of life or increasing overall survival rates
Participants will
Undergo a tumor biopsy
Undergo induction chemotherapy chemotherapy given before radiation therapy with modified FOLFIRINOX FFX or gemcitabine and nab-paclitaxel GnP
If the participants disease remains stable or improves after chemotherapy they will be treated with high dose radiation therapy If the participants cancer progresses after chemotherapy they will be treated by their doctor according to standard of care practices
Complete quality of life questionnaires
Donate research blood samples
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None